Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug 1;35(8):899-906.
doi: 10.1097/MEG.0000000000002582. Epub 2023 Jun 6.

Excellent outcome in patients with primary biliary cholangitis in Northwest Italy followed up for up to 30 years

Cristina Rigamonti  1 , Carla De Benedittis  1 , Sara Labanca  2 , Ester Vanni  3 , Anna Morgando  3 , Giulia Francesca Manfredi  1 , Danila Azzolina  4 , Micol Giulia Cittone  1 , Edoardo Giovanni Giannini  2 , Giorgio Maria Saracco  3 , Mario Pirisi  1
Affiliations

Excellent outcome in patients with primary biliary cholangitis in Northwest Italy followed up for up to 30 years

Cristina Rigamonti et al. Eur J Gastroenterol Hepatol. .

Abstract

Objective: Primary biliary cholangitis (PBC) is a rare chronic autoimmune cholangiopathy, characterized by a variable course and response to treatment. We aimed to describe long-term outcomes of PBC patients referred to three academic centres in Northwest Italy.

Methods: This is an ambispective cohort study of PBC patients (retrospective component: diagnosis before 1 January 2019; prospective component: thereafter), including 302 patients: 101 (33%) followed up in Novara, 86 (28%) in Turin, 115 (38%) in Genoa. Clinical features at diagnosis, biochemical response to therapy and survival were analyzed.

Results: Among the 302 patients (88% women, median age 55 years, median follow-up 75 months), alkaline phosphatase (ALP) levels significantly decreased during treatment with ursodeoxycholic acid (UDCA, P < 0.0001) and obeticholic acid (P < 0.0001). At multivariate analysis, ALP at diagnosis was predictive of 1-year biochemical response to UDCA [odds ratio 3.57, 95% confidence interval (CI) 1.4-9, P < 0.001]. Estimated median survival free of liver transplantation and hepatic complications was 30 years (95% CI 19-41). Bilirubin level at diagnosis was the only independent risk factor for the combined outcome of death, transplantation or hepatic decompensation (hazard ratio, 1.65, 95% CI 1.66-2.56, P = 0.02). Patients presenting with total bilirubin at diagnosis ≥0.6 times the upper normal limit (ULN) had a significantly lower 10-year survival compared to those with bilirubin <0.6 times ULN (63% vs. 97%, P < 0.0001).

Conclusion: In PBC, both short-term response to UDCA and long-term survival can be predicted by simple conventional biomarkers of disease severity, obtained at diagnosis.

PubMed Disclaimer

References

    1. Boonstra K, Kunst AE, Stadhouders PH, Tuynman HA, Poen AC, van Nieuwkerk KM, et al.; Epi PSC PBC study group. Rising incidence and prevalence of primary biliary cirrhosis: a large population-based study. Liver Int 2014; 34:e31–e38.
    1. Hirschfield GM, Gershwin ME. The immunobiology and pathophysiology of primary biliary cirrhosis. Annu Rev Pathol 2013; 8:303–330.
    1. Webb GJ, Hirschfield GM. Primary biliary cholangitis in 2016: high-definition PBC: biology, models and therapeutic advances. Nat Rev Gastroenterol Hepatol 2017; 14:76–78.
    1. Harms MH, Janssen QP, Adam R, Duvoux C, Mirza D, Hidalgo E, et al.; European Liver and Intestine Transplant Association (ELITA). Trends in liver transplantation for primary biliary cholangitis in Europe over the past three decades. Aliment Pharmacol Ther 2019; 49:285–295.
    1. Griffiths L, Dyson JK, Jones DE. The new epidemiology of primary biliary cirrhosis. Semin Liver Dis 2014; 34:318–328.

LinkOut - more resources